SNDX Syndax Pharmaceuticals Inc.

16.2
+0.15  (+1%)
Previous Close 16.05
Open 16.01
Price To Book 10.95
Market Cap 584,737,850
Shares 36,094,929
Volume 904,765
Short Ratio
Av. Daily Volume 979,014
Stock charts supplied by TradingView

NewsSee all news

  1. ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer

    WALTHAM, Mass., May 21, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN Cancer Research Group

  2. Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    WALTHAM, Mass., May 12, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative

  3. Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update

    WALTHAM, Mass., May 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  4. Syndax Announces Pricing of Public Offering of Common Stock

    WALTHAM, Mass., April 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  5. Syndax to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 7, 2020

    WALTHAM, Mass., April 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data March 7, 2019 failed to meet endpoints.
Entinostat plus Tecentriq - ENCORE 603
Ovarian cancer
Phase 2 top-line data March 7, 2019 failed to meet endpoints.
Entinostat plus Tecentriq - ENCORE 602
Triple negative breast cancer (TNBC)
Phase 2 updated data to be presented September 24, 2018 did not meet prespecified ORR endpoint.
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC), colorectal cancer
Phase 3 did not meet overall survival primary endpoint - May 21, 2020.
E2112
HR+, HER2- breast cancer
Phase 1 data to be presented 4Q 2020.
SNDX-6352
Chronic graft versus host disease
Phase 1 additional data due 4Q 2020.
SNDX-5613
Relapsed/refractory (R/R) acute leukemias

Latest News

  1. ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer

    WALTHAM, Mass., May 21, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN Cancer Research Group

  2. Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    WALTHAM, Mass., May 12, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative

  3. Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update

    WALTHAM, Mass., May 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  4. Syndax Announces Pricing of Public Offering of Common Stock

    WALTHAM, Mass., April 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  5. Syndax to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 7, 2020

    WALTHAM, Mass., April 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  6. Syndax Announces Proposed Public Offering of Common Stock

    WALTHAM, Mass., April 29, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  7. Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias

    WALTHAM, Mass., April 27, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  8. Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update

    WALTHAM, Mass., March 3, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  9. Syndax to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 3, 2020

    WALTHAM, Mass., Feb. 25, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  10. Syndax Announces Participation at Two Upcoming Investor Conferences

    WALTHAM, Mass., Feb. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  11. Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million

    WALTHAM, Mass., Jan. 31, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  12. Science Magazine Publishes Results from Preclinical Study on the Activity of Menin-MLL Inhibition for the Treatment of NPM1 Acute Myeloid Leukemia

    WALTHAM, Mass., Jan. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  13. Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook

    WALTHAM, Mass., Jan. 10, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  14. Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease

    WALTHAM, Mass., Dec. 10, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  15. Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias

    WALTHAM, Mass., Dec. 9, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  16. Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update

    WALTHAM, Mass., Nov. 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  17. Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias

    WALTHAM, Mass., Nov. 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  18. Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019

    WALTHAM, Mass., Oct. 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  19. Syndax Announces Participation at Four Upcoming Investor Conferences

    WALTHAM, Mass., Aug. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative